Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ, et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther. 2010;18:570–8.

Article  CAS  PubMed  Google Scholar 

Bailey RM, Rozenberg A, Gray SJ. Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies. Brain Res. 2020;1739:146832.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Dong T, Hu Y, De Pace R, Mattera R, Eberhardt K, et al. Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies. J Clin Invest. 2023;133:e164575.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Lim DA, Lawlor MW, Dimmock D, Vite CH, Lester T, et al. Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration. Hum Gene Ther. 2023;34:94–111.

Article  CAS  PubMed  Google Scholar 

Felix MS, Borloz E, Metwally K, Dauba A, Larrat B, Matagne V, et al. Ultrasound-mediated blood-brain barrier opening improves whole brain gene delivery in mice. Pharmaceutics. 2021;13:1245.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hackett EP, Shah BR, Cheng B, LaGue E, Vemireddy V, Mendoza M, et al. Probing cerebral metabolism with hyperpolarized (13)C imaging after opening the blood-brain barrier with focused ultrasound. ACS Chem Neurosci. 2021;12:2820–8.

Article  CAS  PubMed  Google Scholar 

Lapin NA, Gill K, Shah BR, Chopra R. Consistent opening of the blood brain barrier using focused ultrasound with constant intravenous infusion of microbubble agent. Sci Rep. 2020;10:16546.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parks TV, Szczupak D, Choi SH, Schaeffer DJ. Noninvasive focal transgene delivery with viral neuronal tracers in the marmoset monkey. Cell Rep. Methods. 2024;4:100709.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet. 2003;35:125–7.

Article  CAS  PubMed  Google Scholar 

Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998;20:171–4.

Article  CAS  PubMed  Google Scholar 

Mitra S, Gumusgoz E, Minassian BA. Lafora disease: Current biology and therapeutic approaches. Rev Neurol (Paris). 2022;178:315–25.

Article  CAS  PubMed  Google Scholar 

Duran J, Gruart A, Garcia-Rocha M, Delgado-Garcia JM, Guinovart JJ. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. Hum Mol Genet. 2014;23:3147–56.

Article  CAS  PubMed  Google Scholar 

Pederson BA, Turnbull J, Epp JR, Weaver SA, Zhao X, Pencea N, et al. Inhibiting glycogen synthesis prevents Lafora disease in a mouse model. Ann Neurol. 2013;74:297–300.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet. 2011;7:e1002037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turnbull J, Epp JR, Goldsmith D, Zhao X, Pencea N, Wang P, et al. PTG protein depletion rescues malin-deficient Lafora disease in mouse. Ann Neurol. 2014;75:442–6.

Article  CAS  PubMed  Google Scholar 

Ahonen S, Nitschke S, Grossman TR, Kordasiewicz H, Wang P, Zhao X, et al. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain. 2021;144:2985–93.

Article  PubMed  PubMed Central  Google Scholar 

Gumusgoz E, Kasiri S, Guisso DR, Wu J, Dear M, Verhalen B, et al. AAV-mediated artificial miRNA reduces pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and lafora disease mouse models. Neurotherapeutics. 2022;19:982–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gumusgoz E, Guisso DR, Kasiri S, Wu J, Dear M, Verhalen B, et al. Targeting Gys1 with AAV-SaCas9 decreases pathogenic polyglucosan bodies and neuroinflammation in adult polyglucosan body and lafora disease mouse models. Neurotherapeutics. 2021;18:1414–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nitschke F, Ahonen SJ, Nitschke S, Mitra S, Minassian BA. Lafora disease - from pathogenesis to treatment strategies. Nat Rev Neurol. 2018;14:606–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Varea O, Duran J, Aguilera M, Prats N, Guinovart JJ. Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity. Neurobiol Dis. 2021;147:105173.

Article  CAS  PubMed  Google Scholar 

Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther. 2011;19:1058–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lahuerta M, Gonzalez D, Aguado C, Fathinajafabadi A, Garcia-Gimenez JL, Moreno-Estelles M, et al. Reactive glia-derived neuroinflammation: a novel hallmark in lafora progressive myoclonus epilepsy that progresses with age. Mol Neurobiol. 2020;57:1607–21.

Article  CAS  PubMed  Google Scholar 

Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics-critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11:1138596.

Article  PubMed  PubMed Central  Google Scholar 

Jung O, Thomas A, Burks SR, Dustin ML, Frank JA, Ferrer M, et al. Neuroinflammation associated with ultrasound-mediated permeabilization of the blood-brain barrier. Trends Neurosci. 2022;45:459–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem. 2011;286:13532–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosgrove GR, Lipsman N, Lozano AM, Chang JW, Halpern C, Ghanouni P, et al. Magnetic resonance imaging-guided focused ultrasound thalamotomy for essential tremor: 5-year follow-up results. J Neurosurg. 2023;138:1028–33.

Article  PubMed  Google Scholar 

Natera-Villalba E, Ruiz-Yanzi MA, Gasca-Salas C, Matarazzo M, Martinez-Fernandez R. MR-guided focused ultrasound in movement disorders and beyond: Lessons learned and new frontiers. Parkinsonism Relat Disord. 2024;122:106040.

Article  PubMed  Google Scholar 

Sinai A, Nassar M, Sprecher E, Constantinescu M, Zaaroor M, Schlesinger I. Focused ultrasound thalamotomy in tremor dominant parkinson’s disease: long-term results. J Parkinsons Dis. 2022;12:199–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto K, Ito H, Fukutake S, Odo T, Kamei T, Yamaguchi T, et al. Focused Ultrasound Thalamotomy for Tremor-dominant Parkinson’s Disease: A Prospective 1-year Follow-up Study. Neurol Med Chir (Tokyo. 2021;61(7):414–21.

Meng Y, Pople CB, Suppiah S, Llinas M, Huang Y, Sahgal A, et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 2021;23:1789–97.